Prostate Cancer Biomarker Industry Global Overview: Market Size, Growth Insights and Forecast
Report ID : 1356080 | Published : May 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Prostate Cancer Biomarker Industry is categorized based on Test Type (Protein Biomarkers, Genetic Biomarkers, Cellular Biomarkers, Imaging Biomarkers) and Sample Type (Blood, Urine, Tissue, Saliva) and Application (Diagnosis, Prognosis, Treatment Monitoring, Research) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
The Prostate Cancer Biomarker Industry, valued at $3.5 billion in 2023, is anticipated to expand to $7.1 billion by 2033 at a CAGR of 7.5% from 2024 to 2033. This report covers different segments and offers an analysis of the substantial trends and factors affecting the market.
The Prostate Cancer Biomarker Market is expanding due to improved diagnosis and treatment options for prostate cancer. Prostate cancer continues to be one of the most common types of cancer for men globally, thus increasing the need for reliable diagnostic methods and therapies. Indeed, biomarkers are critical in all aspects of this disease namely detection, prognosis and monitoring thus creating an opportunity for precision medicine and targeted therapy which would improve patient outcomes. The market is set for growth as there is increased emphasis on early diagnosis and treatment, which leads to greater use of biomarker testing among physicians.
In the past few decades, the field of Prostate cancer diagnosis has changed dramatically due to a constellation of efforts being directed towards research and development of new biomarkers. These advancements not just enable to detect prostate cancer in a more precise and timely way, but also assist in the classification of patients according to their risk and their expected responses to treatments. Consequently, all actors in the healthcare system – the drug manufacturers, the diagnostic companies and the research agencies – are very much interested in finding new ways of addressing the ever increasing demands of doctors and patients. The Prostate Cancer Biomarker Market is therefore poised to be one of the dominant areas within the wider oncology space propelling the revolution in the fight against this disease.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Myriad Genetics, Genomic Health, Siemens Healthineers, F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Bristol-Myers Squibb, AstraZeneca, Guardant Health |
| SEGMENTS COVERED |
By Test Type - Protein Biomarkers, Genetic Biomarkers, Cellular Biomarkers, Imaging Biomarkers
By Sample Type - Blood, Urine, Tissue, Saliva
By Application - Diagnosis, Prognosis, Treatment Monitoring, Research
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Prostate Cancer Biomarker Industry Dynamics
The Prostate Cancer Biomarker Industry is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Prostate Cancer Biomarker Industry Segmentations
Market Breakup by Test Type
- Overview
- Protein Biomarkers
- Genetic Biomarkers
- Cellular Biomarkers
- Imaging Biomarkers
Market Breakup by Sample Type
- Overview
- Blood
- Urine
- Tissue
- Saliva
Market Breakup by Application
- Overview
- Diagnosis
- Prognosis
- Treatment Monitoring
- Research
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Prostate Cancer Biomarker Industry
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- Abbott Laboratories
- Roche Diagnostics
- Thermo Fisher Scientific
- Myriad Genetics
- Genomic Health
- Siemens Healthineers
- F. Hoffmann-La Roche AG
- Bio-Rad Laboratories
- Bristol-Myers Squibb
- AstraZeneca
- Guardant Health
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved